BioSpace News Archive

Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, is pleased to announce its participation in the 10th World Congress of Melanoma, a virtual event taking place from April 15 to 17, 2021.

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini’s Chief Medical Officer, effective immediately.

InterVenn Biosciences , the leader in glycoproteomics, announced today that it has developed a glycoproteomics-based signature that accurately predicts which malignant melanoma patients will respond to checkpoint inhibitor therapy.

– NEON-1, clinical trial with ALPN-202 monotherapy, proceeds through dose escalation – – New discovery efforts yield novel preclinical fusion proteins that enable tumor antigen-dependent CD28 costimulation –

- Mirum expands potential opportunities across rare disease pipeline - Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2

Aytu today announced the acquisition of a global license to AR101 (enzastaurin),

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Tim Kelly has been promoted to Chief Operating Officer, effective immediately

Luxfer Holdings PLC (NYSE: LXFR), a global manufacturer of highly-engineered materials, announced today that it will release financial results for the first quarter of 2021 after the market closes on Monday, April 26th, 2021. Luxfer has also scheduled a conference call at 8:30 a.m. U.S. Eastern Time on Tuesday, April 27th, 2021.

Vizient, Inc. today announces that Intermountain Healthcare, based in Salt Lake City, Utah, has signed a 10-year membership agreement that will enable a new level of collaboration as the two companies work together to implement a wide range of solutions and services aimed at providing patients access to high-quality care at the most affordable cost.

Biomarker platform is among the first validated applications of Genialis’ machine learning approach to help predict patient responses to targeted oncology therapies